Headache and Migraine

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed the barriers to the use of preventive medicines.

Considerations for addressing current limitations in the diagnosis and management of migraine in black, indigenous, and people of color.

Reactions to advances in migraine treatment, specifically with the development of disease-specific targeted therapies.

Migraine with aura was associated with the risk of incident hypertension and no significant difference was observed between individuals with or without aura.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.

Acute encephalopathy, coma, and stroke were among clinically diagnosed neurological symptoms that increased mortality risk in patients with COVID-19.

The study will be based in West Haven, Connecticut, and enroll up to 100 veterans with the headache disorder.

Nearly 65% of responders say their migraine disease makes them feel like life is passing them by and more than half claimed they cannot make plans with friends or family because of the unpredictability of their disease.

Here's what is coming soon to NeurologyLive.

Lawrence Severt, MD, PhD, discussed the results from the phase 3 ADVANCE trial of atogepant, and its effect on a number of patient-reported outcomes.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 14, 2021.

Educational resources that health care professionals should consider recommending to help support patients with migraine.

Dr Amaal J. Starling describes her approach to educating patients on treatments for migraine and explains why shared decision making is so important.

In addition to comorbidity frequency, the researchers also studied the comparison of comorbidities between men and women with migraine.

The director at AbbVie discussed the timeline for when a regulatory decision may come for migraine treatment atogepant, and whether additional trials are necessary.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 7, 2021.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University detailed the ways clinicians can tailor their treatment regimens better.

Limitations of current pain scales used by health care professionals who manage patients with migraine, and considerations for using patient diaries to help monitor symptoms and recommend appropriate therapy.

An overview regarding the various phases of migraine and recommendations for using empowering language when educating patients on what to expect from attacks.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Elyse Stock, MD, and Thomas Shiovitz, MD.

A recent review outlined the clinical features, pathophysiology, and treatments for cluster headache, finding noninvasive vagus nerve stimulation to be effective in various ways.

Current hurdles faced by neurologists when prescribing therapy to treat migraine and advice to help other healthcare professionals as well as patients navigate insurance and access issues.

A patient advocate, Jill Dehlin, RN, explains why patients with migraine should connect with other patients via patient support programs and take a proactive role in managing their condition.

The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.